Carnexiv Approval History
- FDA approved: Yes (First approved October 7th, 2016)
- Brand name: Carnexiv
- Generic name: carbamazepine
- Dosage form: Injection
- Company: Lundbeck Inc.
- Treatment for: Seizures
Carnexiv (carbamazepine) is an intravenous injection formulation of the antiepileptic drug carbamazepine indicated as short-term replacement therapy for oral carbamazepine when oral administration is temporarily not feasible.
Carnexiv is administered via intravenous infusion over 30 minutes, every six hours. The total daily dosage of Carnexiv should be 70 percent of the total daily dose of oral carbamazepine, and patients should be switched back to their previous oral carbamazepine regimen as soon as clinically appropriate.
Common side effects include dizziness, somnolence, blurred vision, double vision, headache, infusion-related reactions, infusion site pain, and anemia.
Development History and FDA Approval Process for Carnexiv
|Oct 7, 2016||FDA Approves Carnexiv (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types|
|Apr 22, 2016||FDA Accepts Lundbeck Resubmission of New Drug Application for Carnexiv (carbamazepine)|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.